Walgreens Boots Alliance, Inc. (WBA) Return on Equity (ROE): -87.68%
Is Walgreens Boots Alliance, Inc.’s return on equity (ROE) high or low?
Walgreens Boots Alliance, Inc.'s return on equity (ROE) of -87.68% is 875% below its 5-year average of -9.00%, near the low end of its 5-year range (-87.68%–16.49%).
As of Saturday, June 13, 2026. 78.83% below its 12-month average of -49.03%.
WBA Return on Equity (ROE) Chart
WBA Average Return on Equity (ROE) Chart
WBA Current vs Average Return on Equity (ROE) Chart
WBA Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
-87.68%
RETURN ON EQUITY (ROE) AVG TTM
-49.03%
RETURN ON EQUITY (ROE) AVG 3Y
-18.16%
RETURN ON EQUITY (ROE) AVG 5Y
-9.00%
RETURN ON EQUITY (ROE) AVG 10Y
1.45%
RETURN ON EQUITY (ROE) AVG 15Y
5.46%
RETURN ON EQUITY (ROE) AVG 20Y
8.28%
CURRENT VS TTM AVG
-78.83%
CURRENT VS 3Y AVG
-382.95%
CURRENT VS 5Y AVG
-874.76%
CURRENT VS 10Y AVG
-6154.49%
CURRENT VS 15Y AVG
-1704.39%
CURRENT VS 20Y AVG
-1158.45%
WBA Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Walgreens Boots Alliance, Inc. (WBA) | $10.37B | -87.68% | -49.03% | -18.16% | -9.00% |
| Baxter International Inc. (BAX) | $10.77B | -18.17% | -12.46% | -8.76% | -1.37% |
| Charles River Laboratories International, Inc. (CRL) | $9.03B | -6.28% | -2.13% | 6.32% | 9.65% |
| Tempus AI, Inc. (TEM) | $8.35B | -72.74% | -651.33% | -315.37% | -198.08% |
| Align Technology, Inc. (ALGN) | $12.52B | 10.36% | 10.54% | 10.84% | 19.93% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.73B | 2.46% | -8.94% | -15.72% | 1.14% |
| The Cooper Companies, Inc. (COO) | $13.24B | 2.86% | 4.70% | 4.67% | 11.22% |
| Solventum Corporation (SOLV) | $13.66B | 28.82% | 23.51% | 17.50% | 13.68% |
| Hims & Hers Health, Inc. (HIMS) | $5.98B | -2.97% | 25.09% | 5.57% | 0.40% |
| Hologic, Inc. (HOLX) | $16.97B | 10.37% | 13.30% | 15.60% | 24.66% |
Return Analysis
ROE
-87.7%
ROA
-9.1%
Walgreens Boots Alliance, Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Walgreens Boots Alliance, Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Walgreens Boots Alliance, Inc. (WBA)?
- The return on equity (ROE) for WBA stock is -87.68%.
- Is Walgreens Boots Alliance, Inc.'s return on equity (ROE) high or low?
- Walgreens Boots Alliance, Inc.'s return on equity (ROE) of -87.68% is 875% below its 5-year average of -9.00%, near the low end of its 5-year range (-87.68%–16.49%).
- What is the TTM average return on equity (ROE) for Walgreens Boots Alliance, Inc. (WBA)?
- The TTM average return on equity (ROE) for WBA stock is -49.03%.
- What is the 3Y average return on equity (ROE) for Walgreens Boots Alliance, Inc. (WBA)?
- The 3Y average return on equity (ROE) for WBA stock is -18.16%.
- What is the 5Y average return on equity (ROE) for Walgreens Boots Alliance, Inc. (WBA)?
- The 5Y average return on equity (ROE) for WBA stock is -9.00%.
- What is the 10Y average return on equity (ROE) for Walgreens Boots Alliance, Inc. (WBA)?
- The 10Y average return on equity (ROE) for WBA stock is 1.45%.
- What is the 15Y average return on equity (ROE) for Walgreens Boots Alliance, Inc. (WBA)?
- The 15Y average return on equity (ROE) for WBA stock is 5.46%.
- What is the 20Y average return on equity (ROE) for Walgreens Boots Alliance, Inc. (WBA)?
- The 20Y average return on equity (ROE) for WBA stock is 8.28%.
Walgreens Boots Alliance, Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2024-08-31 | -82.68% |
| 2023-08-31 | -15.38% |
| 2022-08-31 | 14.77% |
| 2021-08-31 | 10.67% |
| 2020-08-31 | 2.16% |
| 2019-08-31 | 16.49% |
| 2018-08-31 | 18.82% |
| 2017-08-31 | 14.42% |
| 2016-08-31 | 13.78% |
| 2015-08-31 | 13.48% |
| 2014-08-31 | 9.40% |
| 2013-08-31 | 13.10% |
| 2012-08-31 | 11.66% |
| 2011-08-31 | 18.28% |
| 2010-08-31 | 14.52% |
| 2009-08-31 | 13.95% |
| 2008-08-31 | 16.76% |
| 2007-08-31 | 18.38% |
| 2006-08-31 | 17.31% |
| 2005-08-31 | 17.54% |
| 2004-08-31 | 16.53% |
| 2003-08-31 | 16.34% |
| 2002-08-31 | 16.36% |
| 2001-08-31 | 17.01% |
| 2000-08-31 | 18.35% |
| 1999-08-31 | 17.91% |
| 1998-08-31 | 17.94% |
| 1997-08-31 | 18.37% |
| 1996-08-31 | 18.19% |
| 1995-08-31 | 17.90% |
Related Metrics
About Walgreens Boots Alliance, Inc.
Walgreens Boots Alliance, Inc., established in 1901 and based in Deerfield, Illinois, operates as a leading global retailer focused on pharmacy, health, and beauty products. Its business activities are organized into two primary divisions: the United States and International. In the United States, the company dispenses prescription drugs and offers a diverse selection of retail goods. This includes items for health, wellness, beauty, and personal care, alongside general merchandise and consumable products, all available through its extensive network of retail drugstores. The U.S. segment also provides specialized central pharmacy services and mail delivery options for prescriptions. As of August 31, 2021, this division managed 8,965 retail outlets under the Walgreens and Duane Reade banners, complemented by five specialty pharmacies. The International segment focuses on the sale of prescription medications, health and wellness items, beauty products, personal care essentials, and other consumer goods. These are sold through its pharmacy-centric health and beauty retail locations, optical practices, its online platform boots.com, and an integrated mobile application. Additionally, this segment engages in pharmaceutical wholesale and distribution operations within Germany. By August 31, 2021, the international portfolio included 4,031 retail stores operating under brands such as Boots, Benavides, and Ahumada, located across countries including the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile. It also oversaw 548 optical practices, with 160 of these operating as franchises.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Timothy C. Wentworth